Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma

• Published in: Cancers Vol. 12; no. 4; p. 869
• Main Authors: Khan, Tashbib, He, Yaowu, Kryza, Thomas, Harrington, Brittney S, Gunter, Jennifer H, Sullivan, Mitchell A, Cuda, Tahleesa, Rogers, Rebecca, Davies, Claire M, Broomfield, Amy, Gough, Madeline, Wu, Andy C, McGann, Thomas, Weroha, S John, Haluska, Paul, Forbes, Josephine M, Armes, Jane E, Barry, Sinead C, Coward, Jermaine I, Jagasia, Nisha, Chetty, Naven, Snell, Cameron E, Lourie, Rohan, Perrin, Lewis C, Hooper, John D
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.04.2020; MDPI
• Subjects: Acidification; Animal models; Cancer therapies; Carboplatin; Cell culture; Chemotherapy; Clinical trials; Glucose; Glycogen; Medical prognosis; Metabolism; Ovarian cancer; Ovarian carcinoma; Patients; Xenografts; 2DG; clear cell ovarian cancer; glycogen

High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we repo...